Antitumor Effects and Normal-Tissue Toxicity of 111In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts

Journal of Nuclear Medicine

Kristin McLarty¹  Susan J. Done¹  Katherine A. Vallis¹  Danny L. Costantini¹  Helen Lee¹  Raymond M. Reilly¹ 

关键词: breast cancer;    trastuzumab (Herceptin);    Auger electrons;    ¹¹¹In;    radioimmunotherapy;   

DOI  :  10.2967/jnumed.109.072389

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

111In-nuclear localization sequence-trastuzumab is a radioimmunotherapeutic agent consisting of trastuzumab modified with NLS peptides (CGYGPKKKRKVGG) and labeled with the Auger electron emitter 111In. Our objectives were to evaluate the tumor growth–inhibitory properties and normal-tissue toxicity of 111In-NLS-trastuzumab in mice after intraperitoneal administration. Methods: The pharmacokinetics of 111In-NLS-trastuzumab after intravenous (tail vein) or intraperitoneal injection in BALB/c mice were compared. Normal-tissue toxicity was determined in BALB/c mice at 2 wk after intraperitoneal injection of 3.7–18.5 MBq (4 mg/kg) of 111In-NLS-trastuzumab by monitoring body weight, histopathologic examination of tissues, and hematology (white blood cell, platelet, red blood cell, and hemoglobin) or clinical biochemistry (alanine transaminase and creatinine) parameters. A no-observable-adverse-effect-level (NOAEL) dose was defined. Athymic mice bearing subcutaneous MDA-MB-361 or MDA-MB-231 human breast cancer xenografts (5.0 × 105 or 0.5 × 105 HER2/cell, respectively) were treated with a single NOAEL dose or 2 doses administered intraperitoneally and separated by 2 wk. Control groups were administered 111In-trastuzumab, trastuzumab, nonspecific 111In-NLS-human IgG (hIgG), or normal saline. Results: The bioavailability of 111In-NLS-trastuzumab after intraperitoneal injection was 0.7. The NOAEL dose was 9.25 MBq (4 mg/kg); doses greater than or equal to 18.5 MBq decreased white blood cell or platelet counts, and doses of 27.7 MBq decreased red blood cell counts. There was no increase in alanine transaminase or creatinine at any doses tested. There were no morphologic changes to the liver, kidneys, heart, or spleen or loss of body weight. A single dose of 111In-NLS-trastuzumab (9.25 MBq)compared with mice receiving 111In-trastuzumab, trastuzumab, 111In-NLS-hIgG, or normal salinesignificantly slowed the rate of growth of MDA-MB-361 tumors over 60 d (0.014 d−1 vs. 0.033 d−1, 0.046 d−1, 0.030 d−1, and 0.061 d−1, respectively; P < 0.05). 111In-NLS-trastuzumab had no effect on the growth of MDA-MB-231 tumors. Two doses of 111In-NLS-trastuzumab (9.25 MBq; 4 mg/kg) separated by 2 wk increased the survival of mice with MDA-MB-361 tumors, compared with mice treated with trastuzumab or normal saline (>140 d vs. 96 and 84 d, respectively; P < 0.001 or 0.027, respectively). Conclusion: 111In-NLS-trastuzumab is a promising radioimmunotherapeutic agent that could be effective for treatment of HER2-overexpressing breast cancer in humans.

【 授权许可】

Unknown